GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Price-to-Owner-Earnings

Gilead Sciences (WBO:GILD) Price-to-Owner-Earnings

: 18.21 (As of Today)
View and export this data going back to 2017. Start your Free Trial

As of today (2024-04-19), Gilead Sciences's share price is €61.92. Gilead Sciences's Owner Earnings per Share (TTM) ended in Dec. 2023 was €3.40. It's Price-to-Owner-Earnings for today is 18.21.


The historical rank and industry rank for Gilead Sciences's Price-to-Owner-Earnings or its related term are showing as below:

WBO:GILD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.61   Med: 16.01   Max: 21280
Current: 18.23

During the past 13 years, the highest Price-to-Owner-Earnings of Gilead Sciences was 21280.00. The lowest was 5.61. And the median was 16.01.


WBO:GILD's Price-to-Owner-Earnings is ranked better than
66.03% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.51 vs WBO:GILD: 18.23

As of today (2024-04-19), Gilead Sciences's share price is €61.92. Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €4.18. Therefore, Gilead Sciences's PE Ratio for today is 14.82.

As of today (2024-04-19), Gilead Sciences's share price is €61.92. Gilead Sciences's EPS without NRI for the trailing twelve months (TTM) ended in was €5.52. Therefore, Gilead Sciences's PE Ratio without NRI for today is 11.23.

During the past 13 years, Gilead Sciences's highest PE Ratio without NRI was 46.47. The lowest was 6.44. And the median was 12.31.


Gilead Sciences Price-to-Owner-Earnings Historical Data

The historical data trend for Gilead Sciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.85 - 11.41 39.13 22.33

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.13 21.49 16.28 17.81 22.33

Competitive Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Price-to-Owner-Earnings falls into.



Gilead Sciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Gilead Sciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=61.92/3.40
=18.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (WBO:GILD) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Gilead Sciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (WBO:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.